WO2022215568A1 - Agent favorisant la synthèse musculaire et agent favorisant la phosphorylation de la protéine p70s6k - Google Patents
Agent favorisant la synthèse musculaire et agent favorisant la phosphorylation de la protéine p70s6k Download PDFInfo
- Publication number
- WO2022215568A1 WO2022215568A1 PCT/JP2022/014842 JP2022014842W WO2022215568A1 WO 2022215568 A1 WO2022215568 A1 WO 2022215568A1 JP 2022014842 W JP2022014842 W JP 2022014842W WO 2022215568 A1 WO2022215568 A1 WO 2022215568A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipoteichoic acid
- muscle
- gram
- acid
- promoting
- Prior art date
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 139
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 89
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 89
- 230000001737 promoting effect Effects 0.000 title claims abstract description 57
- 230000026731 phosphorylation Effects 0.000 title description 9
- 238000006366 phosphorylation reaction Methods 0.000 title description 9
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 title description 2
- 239000002253 acid Substances 0.000 claims abstract description 111
- 206010028289 Muscle atrophy Diseases 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 25
- 230000020763 muscle atrophy Effects 0.000 claims abstract description 25
- 201000000585 muscular atrophy Diseases 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 210000000663 muscle cell Anatomy 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 88
- 241000894006 Bacteria Species 0.000 claims description 52
- 235000014655 lactic acid Nutrition 0.000 claims description 44
- 239000004310 lactic acid Substances 0.000 claims description 44
- 241000192125 Firmicutes Species 0.000 claims description 36
- 241000186660 Lactobacillus Species 0.000 claims description 28
- 229940039696 lactobacillus Drugs 0.000 claims description 28
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 17
- 244000063299 Bacillus subtilis Species 0.000 claims description 16
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 241000186000 Bifidobacterium Species 0.000 claims description 9
- 230000009822 protein phosphorylation Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 230000003244 pro-oxidative effect Effects 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 abstract description 18
- 230000001580 bacterial effect Effects 0.000 abstract description 10
- 230000037081 physical activity Effects 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 238000001262 western blot Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 11
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 11
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 11
- 239000012528 membrane Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000006180 TBST buffer Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000003137 locomotive effect Effects 0.000 description 6
- 239000012620 biological material Substances 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 3
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000006872 mrs medium Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000001076 sarcopenia Diseases 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000012741 Laemmli sample buffer Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- -1 acidulants Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000037147 athletic performance Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000741991 Bifidobacterium mongoliense Species 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- VJDOAZKNBQCAGE-LMVFSUKVSA-N D-ribitol 5-phosphate Chemical compound OC[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O VJDOAZKNBQCAGE-LMVFSUKVSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 101000637726 Homo sapiens Toll/interleukin-1 receptor domain-containing adapter protein Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000394636 Lactobacillus mucosae Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102100032120 Toll/interleukin-1 receptor domain-containing adapter protein Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000025185 skeletal muscle atrophy Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Definitions
- the present invention relates to a muscle synthesis promoter for muscles.
- the present invention also relates to promoters of p70S6K protein phosphorylation.
- Muscles are essential organs for human physical movement. Since increasing muscle mass and strengthening muscle strength leads to improvement in athletic performance, it is a matter of great interest to people who play sports regardless of whether they are professionals or amateurs. Also, for people who do not usually exercise, maintaining and improving muscle mass is an important factor in maintaining good health and leading a smooth daily life.
- Non-Patent Document 1 Whole-body muscle mass is maintained by a balance between muscle synthesis and muscle breakdown. Therefore, preventing muscle atrophy by promoting muscle synthesis and maintaining muscle mass are essential factors for extending healthy life expectancy and improving the QOL of the elderly. Even young people, for example, become temporarily bedridden due to injury or disease, and muscle atrophy easily progresses when the load on muscles decreases, adversely affecting rehabilitation and prognosis. Therefore, preventing muscle atrophy or maintaining muscle mass by promoting muscle synthesis will lead to improved QOL not only for the elderly but also for young people.
- Patent Document 1 discloses that a physical activity promoter containing Lactobacillus gasseri strain OLL2809 as an active ingredient promotes physical activity and increases muscle mass.
- Patent Document 2 discloses a lactobacillus strain of the genus Lactobacillus that promotes myoblast proliferation and muscle repair.
- Patent Document 3 discloses that lipoteichoic acid derived from Lactobacillus carbatus CP2998 strain suppresses muscle degradation.
- Patent document 1 increases muscle mass as a secondary effect associated with promotion of physical activity, but does not directly promote muscle synthesis.
- Patent Document 2 also promotes muscle repair of damaged muscles, and does not promote muscle synthesis in a normal, undamaged state.
- Patent Document 3 discloses that lipoteichoic acid is used as an active ingredient in the same manner as the present invention, but its effect is only to suppress muscle degradation and does not promote differentiation into skeletal muscle. Synthetic acceleration is not disclosed. Also, with regard to muscle degradation inhibition, only the action of lipoteichoic acid derived from a limited strain of lactic acid bacteria has been disclosed. Furthermore, the technique is disclosed as suppressing the degree of muscle breakdown when muscle breakdown is induced, and is intended for patients with advanced muscle atrophy. On the other hand, the present invention is different in that it is effective for muscle cells under normal conditions and is effective not only for sick people but also for healthy people.
- the present invention is to provide a novel technique that contributes to promoting muscle synthesis and preventing muscle atrophy, characterized by directly promoting muscle synthesis without physical activity.
- Muscle synthesis is promoted by activation of the Akt-mTOR (mechanistic target of rapamycin) pathway in muscle cells.
- the p70S6K protein is downstream of the Akt-mTOR pathway and is activated by phosphorylation. Therefore, the amount of phosphorylated p70S6K is used as an indicator of activation of muscle synthesis, and an increase in the amount of phosphorylated p70S6K means activation of muscle synthesis.
- the inventors have found that adding the cell wall of Gram-positive bacteria to muscle cells increases the amount of phosphorylated p70S6K in muscle cells and promotes muscle synthesis.
- the present invention relates to the following inventions [1] to [8].
- [1] A muscle synthesis promoter containing lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid as an active ingredient.
- [2] The muscle synthesis promoter according to [1], wherein the lipoteichoic acid is derived from lactic acid bacteria or Bacillus subtilis, or the Gram-positive bacteria containing lipoteichoic acid is lactic acid bacteria or Bacillus subtilis.
- the lipoteichoic acid is derived from a lactic acid bacterium belonging to the genus Lactobacillus or Bifidobacterium, or the Gram-positive bacterium containing lipoteichoic acid is a lactic acid bacterium belonging to the genus Lactobacillus or Bifidobacterium, [1] ] The muscle synthesis promoter described in ].
- [6] A method of promoting muscle synthesis by causing lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid to act on muscle cells, excluding medical procedures.
- [7] A p70S6K protein phosphorylation promoter containing lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid as an active ingredient.
- p70S6K according to [7], wherein the lactic acid bacterium from which lipoteichoic acid is derived is Lactobacillus gasseri or Lactobacillus delbrechskyi, or the lactic acid bacterium containing lipoteichoic acid is Lactobacillus gasseri or Lactobacillus delbrechskyi Promoter of protein phosphorylation.
- Use of lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid for the production of a muscle synthesis promoter.
- Lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid for use in promoting muscle synthesis.
- a method for promoting muscle synthesis comprising ingesting or administering an effective amount of lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid to a subject in need thereof.
- muscle synthesis is promoted by ingesting Gram-positive bacterial cell walls or lipoteichoic acid, or by directly acting lipoteichoic acid on muscle cells in vivo by a method such as intramuscular injection. can be made In addition, it is possible to increase the muscle mass of livestock by ingesting them as feed.
- 1 is a photograph of Western blotting using an anti-lipoteichoic acid antibody on a fraction obtained in the process of purifying lipoteichoic acid from lactic acid bacteria.
- a strong band was observed in the 25% and 35% propanol fractions, and in the 25% fraction of the extraction from Lactobacillus delbrecci, lipoteichoic acid was purified in this fraction.
- 1 is a Western blot photograph and a quantitative graph showing that Gram-positive bacterial cell walls have an effect of promoting muscle synthesis in Test Example 1.
- FIG. 1 is a Western blot photograph and a quantitative graph showing that a lipoteichoic acid-purified fraction of Lactobacillus gasseri has an effect of promoting muscle synthesis, according to Test Example 1.
- FIG. 1 is a Western blot photograph and a quantitative graph showing that a lipoteichoic acid-purified fraction of Lactobacillus delbreeckii has an effect of promoting muscle synthesis, according to Test Example 1.
- FIG. 2 is a Western blot photograph and a quantitative graph showing that Bacillus subtilis-derived lipoteichoic acid has an effect of promoting muscle synthesis in Test Example 2.
- FIG. FIG. 10 is a Western blot photograph and a quantitative graph showing that the muscle synthesis-promoting effect is mediated by TLR2, according to Test Example 3.
- the present invention provides a muscle synthesis promoter containing Gram-positive bacterial cell wall or lipoteichoic acid as an active ingredient.
- a drug, food, drink, or feed containing gram-positive bacterial cell wall or lipoteichoic acid for promoting muscle synthesis or preventing muscle atrophy, and provide a method for promoting muscle synthesis by causing lipoteichoic acid to act on muscle cells.
- Lipoteichoic acid is one of the cell wall constituents of Gram-positive bacteria and is generally included in Gram-positive bacteria. Moreover, not only the cell wall but also a part thereof is contained in the cell membrane. Lipoteichoic acid consists of long chains of glycerophosphate and ribitol phosphate. Since Gram-positive bacteria generally contain lipoteichoic acid, lipoteichoic acid can be obtained by extraction from suitable Gram-positive bacteria, and lipoteichoic acid derived from Bacillus subtilis is sold as a commercial reagent. In addition, lactic acid bacteria belong to Gram-positive bacteria. Therefore, it is possible to obtain inexpensive and safe lipoteichoic acid by extracting it from lactic acid bacteria that have been used in yogurt, lactic acid beverages, and the like and have been eaten.
- the method for extracting and purifying lipoteichoic acid from Gram-positive bacteria is shown below.
- the medium used for culturing the Gram-positive bacterium is not particularly limited as long as the bacterium can grow, and the bacterium can be cultured by a conventional method.
- the cultured bacteria can be collected by a method such as centrifugation.
- the obtained microbial cells may be used as they are, or the microbial cells subjected to concentration, drying, freeze-drying, and crushing treatment may be used. Cells killed by heat drying or the like can be used.
- After extracting lipoteichoic acid from these cells using water, saline, organic solvents such as butanol, ethyl acetate, chloroform, or a mixture thereof, gel filtration chromatography, hydrophobic chromatography, etc. can be purified by
- lactic acid bacteria belonging to the genus Lactobacillus or Bifidobacterium, or Bacillus subtilis are preferable, and lactic acid bacteria belonging to the genus Lactobacillus or Bifidobacterium are more preferable.
- lactic acid bacteria belonging to the genus Lactobacillus include Lactobacillus acidophilus, Lactobacillus amylovorus, Lactobacillus gasseri, Lactobacillus delbrechky, Lactobacillus helveticus, Lactobacillus johnsonii, Lactobacillus paracasei, and Lactobacillus planus.
- Lactic acid bacteria belonging to the genus Bifidobacterium include Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium breve, and Bifidobacterium.
- Catenulatum Bifidobacterium mongoliense, Bifidobacterium pseudolongum, Bifidobacterium pseudocatenulatum, Bifidobacterium ficari or Bifidobacterium thermophilum are more preferred.
- Most preferred Gram-positive bacteria are Lactobacillus gasseri SBT1848 (NITE-BP03075) or Lactobacillus delbreeckii SBT2002 (NITE-BP03280).
- lipoteichoic acid lipoteichoic acid contained in Lactobacillus gasseri SBT1848 (NITE-BP03075) or Lactobacillus delbrecci SBT2002 (NITE-BP03280) is most preferable.
- the muscle synthesis promoter of the present embodiment may contain lipoteichoic acid, and may be lipoteichoic acid extracted by the method described above, or may be a method using commercially available lipoteichoic acid.
- a method of using Gram-positive bacteria as they are without performing extraction and purification as lipoteichoic acid may be used.
- Gram-positive bacteria When Gram-positive bacteria are used as they are, the Gram-positive bacteria may be concentrated, dried, freeze-dried, or crushed, or killed by heat drying or the like. Therefore, it can be widely used as a composition contained in pharmaceuticals, quasi-drugs, food and drink, feed, and the like.
- the muscle synthesis promoter of this embodiment can be in any form as long as the effects of the present invention can be obtained. That is, it may be in the form of fermented milk, or in other dosage forms.
- Dosage forms include solid or powder formulations such as powders, fine granules, granules, tablets, capsules, and pills, and liquid formulations such as suspensions, emulsions, syrups, and extracts. can be mentioned.
- the administration subject and the daily intake of the agent for preventing muscle atrophy according to the present embodiment are not particularly limited. It can be administered to elderly people, people under the age of 65, and the like. It can also be administered to subjects who have already developed locomotive syndrome or sarcopenia for treatment or alleviation, and can also be administered to healthy subjects who do not yet have such symptoms for prophylaxis.
- the daily intake is also not particularly limited because it varies depending on age, symptoms, body weight, and purpose. 5g.
- locomotive syndrome refers to the functional impairment of one or more locomotive organs such as bones, joints, cartilage, intervertebral discs, and muscles due to aging, resulting in decreased functions such as “standing” and “walking”. It means the state of being
- sarcopenia refers to a syndrome characterized by age-related skeletal muscle atrophy, accompanied by a decrease in skeletal muscle mass and skeletal muscle strength, or a decrease in physical function.
- the terms “promote muscle synthesis” or “promote muscle synthesis” refer to cases in which the agent for promoting muscle synthesis of the present invention is ingested by the subject, and cases in which the agent for promoting muscle synthesis of the present invention is not ingested by the subject. In comparison, it means that there is more synthesis of skeletal muscle. Whether “promoting muscle synthesis” or “promoting muscle synthesis” means that phosphorylation of the p70S6K protein is promoted when the active ingredient is administered to the subject, compared to the subject to which the active ingredient is not administered.
- Examples of the myosynthesis promoter of the present invention include “maintain muscle”, “inhibit muscle atrophy”, “prevent muscle weakening”, “suppress muscle weakening”, “build muscle”, “ Increases muscle”, “builds muscle”, “promotes muscle synthesis”, “supports the ability to build muscle”, “helps prevent loss of muscle mass and strength”, “maintains muscle that declines with age” It is possible to display functions that are useful for” or that can be equated with these.
- the above-mentioned “indication” includes everything that informs consumers of the above functions, and the object to be displayed is regardless of the medium such as the muscle synthesis promoter itself, packaging, containers, catalogs, pamphlets, and Internet homepages. .
- p70S6K protein phosphorylation accelerator As used herein, "p70S6K protein” means the p70 ribosomal S6 kinase protein.
- p70S6K p70 ribosomal protein S6 kinase
- the p70S6K protein is downstream of the Akt-mTOR pathway and is activated by phosphorylation.
- the p70S6K protein phosphorylation promoting agent of the present invention can be labeled with a function that is exhibited by promoting p70S6K protein phosphorylation.
- the food or drink for promoting muscle synthesis or preventing muscle atrophy of the present invention may be any food or drink containing lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid, and may be general food or drink, or food for specified health use. , foods with function claims, dietary supplements, and supplements. Lactic acid beverages, cheese, yogurt and the like are examples of foods and drinks containing Gram-positive bacteria containing lipoteichoic acid.
- Specific examples of the food and drink for promoting muscle synthesis or preventing muscle atrophy of the present invention include carbonated drinks, various fruit juices, fruit juice drinks, soft drinks containing fruit juice, fruit drinks, fruit drinks containing fruit grains, and vegetables including various vegetables.
- beverages soymilk/soymilk drinks, coffee drinks, tea drinks, powdered drinks, concentrated drinks, sports drinks, nutritional drinks, and other alcoholic beverages; caramel/candy, chewing gum, chocolate, cookies/biscuits, cakes/pies, snacks Confectionery such as crackers, Japanese confectionery, rice confectionery, bean confectionery, dessert confectionery; Butter, margarine, mayonnaise, vegetable oil and other fats and oils; Milk, processed milk, milk drinks, yogurts, lactic acid beverages, cheese, ice cream Milk and dairy products such as powdered milk, cream, processed agricultural products such as cereals (processed grains), baby food, and other commercially available foods such as liquid diet.
- the food and drink for promoting muscle synthesis or preventing muscle atrophy of the present invention may optionally contain antioxidants, flavoring agents, acidulants, coloring agents, emulsifiers, preservatives, seasonings, sweeteners, spices, pH adjusters, and stabilizers. agents, vegetable oils, animal oils, sugars and sugar alcohols, vitamins, organic acids, fruit juice extracts, vegetable extracts, grains, beans, vegetables, meats, seafood, and other additives and materials alone or in combination of two or more. can be blended together. The blending amounts of these materials and additives can be determined as appropriate.
- the form of the food and drink for promoting muscle synthesis or preventing muscle atrophy of the present invention is not particularly limited. , semi-liquid, gel form, solid, bar, powder form.
- the amount of lipoteichoic acid for promoting muscle synthesis or preventing muscle atrophy in these foods and drinks is not particularly limited because it varies depending on the form, dosage form, symptoms, body weight, application, etc. of the subject to be administered. It can be blended at, for example, 0.001 to 100 (w/w)%, 0.01 to 10 (w/w), or 0.1 to 1 (w/w)% on the basis of food and drink.
- the above compounding amount is the compounding amount as lipoteichoic acid.
- the feed for promoting muscle synthesis or preventing atrophy may be obtained by mixing the above-mentioned active ingredient with a normal feed, or by administering lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid.
- the present embodiment can provide a novel muscle synthesis promoter.
- This muscle synthesis accelerator contains lipoteichoic acid, which is generally contained in Gram-positive bacteria, as an active ingredient. If positive bacteria are used, highly safe products can be provided.
- the mixture was separated into an aqueous layer, an intermediate layer and a butanol layer.
- the aqueous layer was collected and the solvent was removed by lyophilization.
- the resulting extract was dissolved in 5 mL of 15% propanol/0.1 M sodium acetate aqueous solution to obtain a crude lipoteichoic acid fraction.
- the lipoteichoic acid crude fraction was then centrifuged and the supernatant filtered through a 0.22 ⁇ m filter.
- a 1 mL Hitrap Octyl FF column (GE Healthcare) was equilibrated with a 15% propanol/sodium acetate aqueous solution, and 1 mL of the crude fraction supernatant was applied to the column.
- lipoteichoic acid was purified to fractions eluted with 25% and 35% propanol/sodium acetate aqueous solutions in the extraction from Lactobacillus gasseri, and in the 25% fraction in the extraction from Lactobacillus delbrecci. (Fig. 1).
- each fraction obtained in the process of lipoteichoic acid purification from lactic acid bacteria cell walls or strains was added.
- the cells were washed with PBS and lysed using Alpha SureFire Ultra Lysis Buffer (PerkinElmer).
- the cell lysate was collected and centrifuged to obtain the supernatant to obtain the sample for subsequent Western blotting.
- Each sample was mixed with Laemmli sample buffer and heated at 90°C for 10 minutes for denaturation. The heated sample was applied to a 4-20% Criterion TGX gel (Bio-Rad) and electrophoresed at 200V constant pressure for 40 minutes.
- the membrane was washed with TBST, immersed in HRP-labeled secondary antibody (Anti-rabbit IgG HRP-linked Antibody; Cell Signaling Technology) diluted 10,000 times with blocking buffer, and shaken for 1 hour. After secondary antibody reaction, the membrane was washed with TBST and reacted for 5 minutes using ECL Prime Western Blotting Detection Reagent or Clarity Max Western ECL Substrate (Bio-Rad). After completion of the reaction, signals were detected with Chemi Doc MP (Bio-Rad). After quantifying the signal intensity, the muscle synthesis promoting effect was evaluated by dividing the phosphorylated p70S6K value by the total p70S6K value.
- HRP-labeled secondary antibody Anti-rabbit IgG HRP-linked Antibody; Cell Signaling Technology
- propanol fractions which are purified fractions of lactic acid bacteria cell walls and lipoteichoic acid, were found to have muscle synthesis promoting activity (Figs. 2, 3 and 4). Since lipoteichoic acid is one of the cell wall constituents, it is contained in both the sediment (cell wall fraction) and the supernatant (soluble fraction) after centrifugation of the disrupted cells.
- the control group was supplemented with the supernatant of the disrupted bacterial cells, which was found to have muscle synthesis-promoting activity. After recovering the cells, Western blotting was performed to evaluate the effect of promoting muscle synthesis. As a result, Bacillus subtilis-derived lipoteichoic acid was found to promote muscle synthesis at concentrations of 100 ng/mL or higher (Fig. 5).
- TLR2 Toll-like receptor 2
- TLR2 Toll-like receptor 2
- muscle synthesis can be promoted or muscle atrophy can be prevented by Gram-positive bacterial cell walls or lipoteichoic acid.
- muscle strength can be maintained and improved, healthy life expectancy can be extended, and QOL can be improved.
- SBT1848 strain B Name and address of the depositary institution that deposited the biological material National Institute of Technology and Evaluation Patent Microorganism Depositary Center (2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture (zip code 292-0818) ) Date of depositing the biological material at Roy's depository: November 25, 2019 (original date of deposit) September 10, 2021 (the date of transfer from the original deposit to the deposit under the Budapest Treaty) Accession number NITE BP-03075 assigned to the deposit by the depositary institution of Hai (2) SBT2002 strain A.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Physiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Le but de la présente invention est de fournir une nouvelle technique pour favoriser directement la synthèse musculaire sans activité physique et prévenir l'atrophie musculaire. L'invention concerne : un agent favorisant la synthèse musculaire ou un agent de prévention de l'atrophie musculaire contenant une paroi cellulaire bactérienne à gram positif ou un acide lipotéichoïque en tant que principe actif; ou un procédé pour favoriser la synthèse musculaire en permettant à une paroi cellulaire bactérienne à gram positif ou à un acide lipotéichoïque d'agir sur des cellules musculaires.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023512947A JPWO2022215568A1 (fr) | 2021-04-08 | 2022-03-28 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021065572 | 2021-04-08 | ||
JP2021-065572 | 2021-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022215568A1 true WO2022215568A1 (fr) | 2022-10-13 |
Family
ID=83545422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/014842 WO2022215568A1 (fr) | 2021-04-08 | 2022-03-28 | Agent favorisant la synthèse musculaire et agent favorisant la phosphorylation de la protéine p70s6k |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2022215568A1 (fr) |
TW (1) | TW202304470A (fr) |
WO (1) | WO2022215568A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013502456A (ja) * | 2009-08-26 | 2013-01-24 | アールエヌエー アイエヌシー | リポタイコ酸由来の糖脂質及びこれを含む組成物 |
JP2013047192A (ja) * | 2011-08-29 | 2013-03-07 | Meiji Co Ltd | 身体活動を促進させる乳酸菌 |
WO2015068809A1 (fr) * | 2013-11-07 | 2015-05-14 | サントリーホールディングス株式会社 | Agent d'amélioration de la fonction de barrière intestinale contenant un ferment lactique |
JP2018083761A (ja) * | 2016-11-21 | 2018-05-31 | アサヒグループホールディングス株式会社 | 筋肉の分解抑制剤 |
-
2022
- 2022-03-28 WO PCT/JP2022/014842 patent/WO2022215568A1/fr active Application Filing
- 2022-03-28 JP JP2023512947A patent/JPWO2022215568A1/ja active Pending
- 2022-03-31 TW TW111112382A patent/TW202304470A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013502456A (ja) * | 2009-08-26 | 2013-01-24 | アールエヌエー アイエヌシー | リポタイコ酸由来の糖脂質及びこれを含む組成物 |
JP2013047192A (ja) * | 2011-08-29 | 2013-03-07 | Meiji Co Ltd | 身体活動を促進させる乳酸菌 |
WO2015068809A1 (fr) * | 2013-11-07 | 2015-05-14 | サントリーホールディングス株式会社 | Agent d'amélioration de la fonction de barrière intestinale contenant un ferment lactique |
JP2018083761A (ja) * | 2016-11-21 | 2018-05-31 | アサヒグループホールディングス株式会社 | 筋肉の分解抑制剤 |
Non-Patent Citations (2)
Title |
---|
AISO, CHISATO: "Effects of Lactococcus lactis subsp. cremoris FC-fermented milk on muscle mass and protein metabolism signaling in aged mice", THE JOURNAL OF PHYSICAL FITNESS AND SPORTS MEDICINE, vol. 9, no. 6, 25 November 2020 (2020-11-25), pages 305, XP009535208, ISSN: 2186-8131 * |
SIJTSMA L, WOUTERS J T, HELLINGWERF K J: "Isolation and characterization of lipoteichoic acid, a cell envelope component involved in preventing phage adsorption, from Lactococcus lactis subsp. cremoris SK110", JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 172, no. 12, 1 December 1990 (1990-12-01), US , pages 7126 - 7130, XP055976557, ISSN: 0021-9193, DOI: 10.1128/jb.172.12.7126-7130.1990 * |
Also Published As
Publication number | Publication date |
---|---|
TW202304470A (zh) | 2023-02-01 |
JPWO2022215568A1 (fr) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8501169B2 (en) | Microorganisms for improving the health of individuals with disorders related to gluten ingestion | |
JP5923238B2 (ja) | 迷走神経活性化剤 | |
AU2019243093B2 (en) | Nutritional composition, food/drink composition using nutritional composition, and modified milk powder using nutritional composition | |
US11607435B2 (en) | Probiotics Bifidobacteria strains | |
NO327792B1 (no) | Bifidobakteriumstamme, formulering omfattende nevnte stamme, og anvendelse derav i matprodukter eller medikamenter ved behandling av sykdom. | |
CA2824619A1 (fr) | Bifidobacterium cect 7765 et son utilisation pour prevenir et/ou traiter le surpoids, l'obesite et les pathologies associees | |
SG177743A1 (en) | Novel lactobacillus plantarum and composition comprising same | |
JP6923883B2 (ja) | 栄養状態改善に使用するための組成物 | |
Ahmad et al. | Therapeutic aspects of probiotics and prebiotics | |
KR102224072B1 (ko) | 면역 조절능력과 혈중콜레스테롤 감소 능력이 모두 뛰어난 비피도박테리엄 롱검 아종 균주 및 이의 용도 | |
JP2018177703A (ja) | Toll様受容体2活性化用組成物 | |
JP5950993B2 (ja) | 迷走神経活性化剤 | |
WO2022215568A1 (fr) | Agent favorisant la synthèse musculaire et agent favorisant la phosphorylation de la protéine p70s6k | |
EP3479836B1 (fr) | Composition facilitant la régénération du cartilage | |
Lau et al. | Probiotics: Health benefits, food application, and colonization in the human gastrointestinal tract | |
Lavermicocca et al. | Table olives: a carrier for delivering probiotic bacteria to humans | |
da Motta et al. | Probiotics in milk and dairy foods | |
WO2020116511A1 (fr) | Composition servant à la suppression d'une infection au norovirus | |
TW201138651A (en) | Agent for controlling the increase and decrease of lactobacillus bifidus in colon | |
JP2021180619A (ja) | 整腸用茶発酵組成物及びその製造方法 | |
WO2017057307A1 (fr) | Élément de contrôle de production d'anticorps | |
US20220387522A1 (en) | Composition for enhancing or improving immune system comprising bifidobacterium bifidum | |
EP4289485A1 (fr) | Composition ayant un effet immunostimulant | |
EP3858363A1 (fr) | Composition pour le traitement des maladies intestinales ou pulmonaires | |
Sankova et al. | SARS-CoV-2 and microbiome: pathology, implications and therapeutic options |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22784553 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023512947 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22784553 Country of ref document: EP Kind code of ref document: A1 |